Mesenchymal stem cells after acute myocardial infarction.
Recruiting
- Conditions
- Acute myocardial infarction
- Registration Number
- NL-OMON24674
- Lead Sponsor
- Investigator-initiated study.Principal investigator: dr. D.E. Atsma
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 48
Inclusion Criteria
1.Acute ST segment elevation myocardial infarction treated by successful primary PTCA of the infarct related coronary artery within 12 hours after onset of chest pain
2.Increase in CPK levels >1600 U/L
Exclusion Criteria
1.Previous myocardial infarction or CABG
2.Evidence of cancer (except low grade and fully resolved non-melanoma skin malignancy)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Safety and feasibility of intramyocardial injection of ex vivo expanded mesenchymal stem cells after primary PTCA for acute myocardial infarction
- Secondary Outcome Measures
Name Time Method - To assess the efficacy of autologous bone marrow-derived in vitro expanded mesenchymal stem cell transplantation after successful primary PTCA for acute myocardial infarction:<br /><br>-Infarct size assessed by gated SPECT (baseline vs. 3 months)<br /><br>-Left ventricular ejection fraction, left ventricular end-diastolic volume and left ventricular end-systolic volume as assessed by gated SPECT (baseline vs. 3 months)<br>